07.03.2024 A meeting of the Methodological Commission of the State Scientific-Research Control Institute of Veterinary Medicinal Products and Feed Additives was held under the chairmanship of the Acting Director of the Institute, Doctor of Veterinary Sciences, Professor Volodymyr Stybel, and the Deputy Director for Scientific Work, PhD in Vet., Iryna Mazur.
During the meeting, the work programmes and schedules of the laboratories of the Institute in 2024 were reviewed. In particular, Orest Vezdenko, Deputy Head of the Agency for Veterinary Drugs and Feed Additives, PhD in Chemistry Mariana Rydchuk, Head of the Laboratory for High Performance Liquid Chromatography, PhD in Biology Roman Ostapiv, Head of the Laboratory for Control of Feed Additives and Premixes, PhD in Vet. Halyna Ryvak, Head of the Laboratory for Bacteriological Control of Quality and Safety of Veterinary Preparations, Dr. Ihor Kushnir, Head of the Laboratory for Clinical and Biological Research, PhD in Biology, Oksana Pyatnychko, Head of the Laboratory of Pharmacology and Toxicology, PhD in Vet., Ihor Paterega, Head of the Laboratory of Control of Chemotherapeutic Drugs, PhD in Agriculture Taras Stetsko.
The meeting took place in a friendly and supportive atmosphere. Almost every report provoked active discussion among colleagues. In particular, Dr. Yuriy Kosenko, Deputy Director for International Cooperation and European Scientific Integration, shared ideas for establishing cooperation between the Institute and colleagues from EMA and EFSA.Dr. Dmytro Yanovych, Deputy Director for Scientific Support of the Testing Quality System, made a number of sensible suggestions for implementing European approaches to research. Dr. Viktor Muzyka, Deputy Director for Information Work, outlined the most problematic aspects of planning clinical and toxicological trials.
At the end of the meeting, the Acting Director, Doctor of Veterinary Sciences, Professor Volodymyr Stybel, noted the high professional level of the staff of the Institute and expressed his sincere hope that, despite the difficult times the whole country is going through today, we will be able to keep the team together and once again confirm the image of the Institute as a unique professional scientific environment serving as a link between modern pharmaceutical science and business.
ах
